Cargando…
Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation
Pulmonary fibrosis (PF) is one of the sequelae of Corona Virus Disease 2019 (COVID-19), and currently, lung transplantation is the only viable treatment option. Hence, other effective treatments are urgently required. We investigated the therapeutic effects of an approved botanical drug, cepharanthi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864377/ https://www.ncbi.nlm.nih.gov/pubmed/36677811 http://dx.doi.org/10.3390/molecules28020753 |
_version_ | 1784875569324752896 |
---|---|
author | Chen, Guangrui Li, Jian Liu, Huimeng Zhou, Huiyu Liu, Mingqiu Liang, Di Meng, Zhiyun Gan, Hui Wu, Zhuona Zhu, Xiaoxia Han, Peng Liu, Taoyun Gu, Ruolan Liu, Shuchen Dou, Guifang |
author_facet | Chen, Guangrui Li, Jian Liu, Huimeng Zhou, Huiyu Liu, Mingqiu Liang, Di Meng, Zhiyun Gan, Hui Wu, Zhuona Zhu, Xiaoxia Han, Peng Liu, Taoyun Gu, Ruolan Liu, Shuchen Dou, Guifang |
author_sort | Chen, Guangrui |
collection | PubMed |
description | Pulmonary fibrosis (PF) is one of the sequelae of Corona Virus Disease 2019 (COVID-19), and currently, lung transplantation is the only viable treatment option. Hence, other effective treatments are urgently required. We investigated the therapeutic effects of an approved botanical drug, cepharanthine (CEP), in a cell culture model of transforming growth factor-β1 (TGF-β1) and bleomycin (BLM)-induced pulmonary fibrosis rat models both in vitro and in vivo. In this study, CEP and pirfenidone (PFD) suppressed BLM-induced lung tissue inflammation, proliferation of blue collagen fibers, and damage to lung structures in vivo. Furthermore, we also found increased collagen deposition marked by α-smooth muscle actin (α-SMA) and Collagen Type I Alpha 1 (COL1A1), which was significantly alleviated by the addition of PFD and CEP. Moreover, we elucidated the underlying mechanism of CEP against PF in vitro. Various assays confirmed that CEP reduced the viability and migration and promoted apoptosis of myofibroblasts. The expression levels of myofibroblast markers, including COL1A1, vimentin, α-SMA, and Matrix Metallopeptidase 2 (MMP2), were also suppressed by CEP. Simultaneously, CEP significantly suppressed the elevated Phospho-NF-κB p65 (p-p65)/NF-κB p65 (p65) ratio, NOD-like receptor thermal protein domain associated protein 3 (NLRP3) levels, and elevated inhibitor of NF-κB Alpha (IκBα) degradation and reversed the progression of PF. Hence, our study demonstrated that CEP prevented myofibroblast activation and treated BLM-induced pulmonary fibrosis in a dose-dependent manner by regulating nuclear factor kappa-B (NF-κB)/ NLRP3 signaling, thereby suggesting that CEP has potential clinical application in pulmonary fibrosis in the future. |
format | Online Article Text |
id | pubmed-9864377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98643772023-01-22 Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation Chen, Guangrui Li, Jian Liu, Huimeng Zhou, Huiyu Liu, Mingqiu Liang, Di Meng, Zhiyun Gan, Hui Wu, Zhuona Zhu, Xiaoxia Han, Peng Liu, Taoyun Gu, Ruolan Liu, Shuchen Dou, Guifang Molecules Article Pulmonary fibrosis (PF) is one of the sequelae of Corona Virus Disease 2019 (COVID-19), and currently, lung transplantation is the only viable treatment option. Hence, other effective treatments are urgently required. We investigated the therapeutic effects of an approved botanical drug, cepharanthine (CEP), in a cell culture model of transforming growth factor-β1 (TGF-β1) and bleomycin (BLM)-induced pulmonary fibrosis rat models both in vitro and in vivo. In this study, CEP and pirfenidone (PFD) suppressed BLM-induced lung tissue inflammation, proliferation of blue collagen fibers, and damage to lung structures in vivo. Furthermore, we also found increased collagen deposition marked by α-smooth muscle actin (α-SMA) and Collagen Type I Alpha 1 (COL1A1), which was significantly alleviated by the addition of PFD and CEP. Moreover, we elucidated the underlying mechanism of CEP against PF in vitro. Various assays confirmed that CEP reduced the viability and migration and promoted apoptosis of myofibroblasts. The expression levels of myofibroblast markers, including COL1A1, vimentin, α-SMA, and Matrix Metallopeptidase 2 (MMP2), were also suppressed by CEP. Simultaneously, CEP significantly suppressed the elevated Phospho-NF-κB p65 (p-p65)/NF-κB p65 (p65) ratio, NOD-like receptor thermal protein domain associated protein 3 (NLRP3) levels, and elevated inhibitor of NF-κB Alpha (IκBα) degradation and reversed the progression of PF. Hence, our study demonstrated that CEP prevented myofibroblast activation and treated BLM-induced pulmonary fibrosis in a dose-dependent manner by regulating nuclear factor kappa-B (NF-κB)/ NLRP3 signaling, thereby suggesting that CEP has potential clinical application in pulmonary fibrosis in the future. MDPI 2023-01-11 /pmc/articles/PMC9864377/ /pubmed/36677811 http://dx.doi.org/10.3390/molecules28020753 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Guangrui Li, Jian Liu, Huimeng Zhou, Huiyu Liu, Mingqiu Liang, Di Meng, Zhiyun Gan, Hui Wu, Zhuona Zhu, Xiaoxia Han, Peng Liu, Taoyun Gu, Ruolan Liu, Shuchen Dou, Guifang Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation |
title | Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation |
title_full | Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation |
title_fullStr | Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation |
title_full_unstemmed | Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation |
title_short | Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation |
title_sort | cepharanthine ameliorates pulmonary fibrosis by inhibiting the nf-κb/nlrp3 pathway, fibroblast-to-myofibroblast transition and inflammation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864377/ https://www.ncbi.nlm.nih.gov/pubmed/36677811 http://dx.doi.org/10.3390/molecules28020753 |
work_keys_str_mv | AT chenguangrui cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT lijian cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT liuhuimeng cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT zhouhuiyu cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT liumingqiu cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT liangdi cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT mengzhiyun cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT ganhui cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT wuzhuona cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT zhuxiaoxia cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT hanpeng cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT liutaoyun cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT guruolan cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT liushuchen cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation AT douguifang cepharanthineamelioratespulmonaryfibrosisbyinhibitingthenfkbnlrp3pathwayfibroblasttomyofibroblasttransitionandinflammation |